Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM
Authors:
- Nitasha SarswatNSNitasha Sarswat
- Amrut V AmbardekarAAAmrut V Ambardekar
- Kevin M AlexanderKAKevin M Alexander
- Sarah Am CuddySCSarah Am Cuddy
- Lily SternLSLily Stern
- Steen Hvitfeldt PoulsenSPSteen Hvitfeldt Poulsen
- Carsten TschöpeCTCarsten Tschöpe
- Yoshiki SekijimaYSYoshiki Sekijima
- Farooq H SheikhFSFarooq H Sheikh
- Jan M GriffinJGJan M Griffin
- Daniel P JudgeDJDaniel P Judge
- Julian GillmoreJGJulian Gillmore
Open Access
- 1 February 2026
- journal article
- review article
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (2) , 119-133
Abstract
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. TTR stabilizers bind directly to TTR, inhibiting tetramer dissociation and the resulting amyloidogenic process. This comprehensive review synthesizes clinical outcomes data from the ATTRibute-CM study program, including primary analyses, prespecified sensitivity studies, and open-label extension (OLE) follow-up, to characterize the clinical profile of acoramidis, an oral TTR stabilizer approved for ATTR-CM treatment. In clinical trials, acoramidis demonstrated consistent clinical benefits, with statistically significant reductions in the composite of all-cause mortality or first cardiovascular-related hospitalization evident within 3 months and sustained through 30 months. Prespecified analyses confirmed treatment robustness. Efficacy was maintained regardless of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) thresholds (≥500 pg/mL, ≥750 pg/mL, and ≥1000 pg/mL), was unaffected by concomitant tafamidis use, and was similar in high-risk participants with stage 4 chronic kidney disease (CKD), who are typically excluded from clinical trials. OLE studies through 42 months showed sustained benefits with no new safety concerns. Results demonstrate robust clinical benefits of acoramidis across diverse ATTR-CM populations and across NYHA classes and NAC stages, independent of NT-proBNP thresholds, concomitant tafamidis use, or high-risk CKD. An ongoing prevention study in asymptomatic ATTR-CM gene-mutation carriers may further expand its therapeutic range for ATTR management.Keywords
Funding Information
- BridgeBio Pharma, Inc. San Francisco, CA
This publication has 36 references indexed in Scilit:
- Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-UpJournal of Cardiac Failure, 2025
- Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variabilityJournal of Neurology, 2024
- Stratifying Disease Progression in Patients With Cardiac ATTR AmyloidosisJACC, 2024
- Cardiac Amyloidosis Due to Transthyretin ProteinJAMA, 2024
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac AmyloidosisJACC, 2023
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyJACC, 2019
- First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult VolunteersClinical Pharmacology in Drug Development, 2019
- Transthyretin Amyloid CardiomyopathyJACC, 2019
- Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging SystemJACC, 2016
- Combining mortality and longitudinal measures in clinical trialsStatistics in Medicine, 1999